Inventor · disambiguated record
Kevin T. Mellem
Also filed as: MELLEM KEVIN · MELLEM KEVIN T
12 granted patents·6 pending applications·55 citations·filing 2016–2023
88Inventor score
Files withREVOLUTION MEDICINES INC13MAZE THERAPEUTICS INC2SFUNGA THERAPEUTICS INC2KINESID THERAPEUTICS INC1
Top patents by PatentIndex Score
18 records- 0195US10980889B1C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Apr 20, 2021·8 cites·6 claims
- 0294US10590090B22,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2018·Granted Mar 17, 2020·28 cites·50 claims
- 0389US9957290B2Derivatives of amphotericin BREVOLUTION MEDICINES INC·Filed 2016·Granted May 1, 2018·8 cites·18 claims
- 0488US11814367B2Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereofMAZE THERAPEUTICS INC·Filed 2022·Granted Nov 14, 2023·4 cites·41 claims
- 0583US10597420B2Derivatives of amphotericin BSFUNGA THERAPEUTICS INC·Filed 2018·Granted Mar 24, 2020·4 cites·20 claims
- 0680US10882883B2Derivatives of amphotericin BSFUNGA THERAPEUTICS INC·Filed 2020·Granted Jan 5, 2021·1 cites·24 claims
- 0777US11673896B2Pyridine compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Jun 13, 2023·1 cites·16 claims
- 0875US11739093B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Aug 29, 2023·1 cites·18 claims
- 0971US12365688B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Jul 22, 2025·0 cites·36 claims
- 1070US2024067636A1Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 1170US2024101577A1Polycyclic compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 1270US2024092795A1Pyridine compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 1368US2019336609A1C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR InhibitorsREVOLUTION MEDICINES INC·Filed 2019·Application pending·0 cites
- 1466US11702411B2Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jul 18, 2023·0 cites·6 claims
- 1561US11661401B22,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted May 30, 2023·0 cites·11 claims
- 1660US11673901B2Polycyclic compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jun 13, 2023·0 cites·19 claims
- 1758US2024199546A1Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereofMAZE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1850US2024018105A1Tropolone derivatives and tautomers thereof for iron regulation in animalsKINESID THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kevin T. Mellem files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →